Drug Information

General Information
Drug ID
DR00265
Drug Name
Lenvatinib
Synonyms
4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide; E-7080, E7080; E7080
Drug Type
Small molecular drug
Indication Ovarian cancer [ICD11: 2C73] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C21H19ClN4O4
Canonical SMILES
COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
InChI
InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
InChIKey
WOSKHXYHFSIKNG-UHFFFAOYSA-N
CAS Number
CAS 204460-24-2
Pharmaceutical Properties Molecular Weight 426.9 Topological Polar Surface Area 116
Heavy Atom Count 30 Rotatable Bond Count 6
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 5
XLogP
2.8
PubChem CID
9823820
PubChem SID
123098996 , 123110209 , 124757043 , 125163847 , 125749042 , 126665901 , 131314303 , 131480711 , 134221774 , 135262444 , 135626656 , 135685148 , 135685149 , 135685168 , 136367339 , 136367958 , 137262627 , 137276042 , 139802275 , 144115929 , 14782907 , 152258284 , 152344144 , 160647123 , 162011787 , 162037768 , 162527769 , 164041901 , 174560999 , 178103998 , 180386840 , 198978519 , 202553041 , 223669921 , 223705252 , 223913134 , 227134592 , 24126764 , 242060265 , 247802696 , 251911433 , 251971223 , 252150297 , 252215326 , 252215327 , 252451828 , 252543308 , 44859775 , 74753053 , 99436922
ChEBI ID
ChEBI:85994
TTD Drug ID
D0R0FO
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 Lenvatinib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 2019 Apr 1;9(1):5404.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.